皮膚纖維化治療市場:按藥物類型、給藥途徑、應用、分銷渠道、地區 - 規模、份額、前景和機會分析，2022-2030 年

真皮纖維化通常發生在患有嗜酸性粒細胞肌痛綜合徵、硬化性粘液水腫（乳頭狀粘液病）和上瞼下垂的患者中。纖維化通常是由於持續接觸化學物質或傷害表皮或真皮的創傷而發展起來的。纖維化的特徵是真皮或皮下組織中纖維結締組織的增加，並且通常與持續性炎症有關。纖維化通常是由於反復接觸化學品或外傷引起的表皮或真皮損傷而發展起來的。真皮纖維結締組織的增加是這種疾病的標誌之一。系統性硬化症主要是皮膚纖維化，儘管它會導致許多其他器官的纖維化。雖然這種纖維化無法逆轉，但目前市售的藥物可以在一定程度上對其進行治療。皮膚纖維化是由傷口癒合的病理反應引起的，導致皮膚過度疤痕。硬皮病、腎源性纖維皮膚病、混合性結締組織病、硬皮病、肉芽腫和嗜酸性筋膜炎只是眾多纖維化皮膚病中的一小部分。

市場動態

皮膚纖維化治療的最新進展預計將在預測期內推動全球皮膚纖維化治療市場的增長。例如，2017 年 12 月，施普林格自然 (Springer Nature) 發表的數據顯示，新的治療策略在治療真皮纖維化方面取得了可喜的成果。在該療法中，使用單克隆抗體進行分子靶向治療。利妥昔單抗（抗 CD20 抗體）和托珠單抗（抗白細胞介素 6 (IL-6) 受體抗體）已報告了良好的臨床結果。

這項研究的主要特點

• 本報告對全球皮膚纖維化治療市場進行了深入分析，闡述了以 2021 年為基準年的預測期 (2022-2030) 的市場規模和復合年增長率 (CAGR%)。
• 它揭示了不同細分市場的潛在收入機會，並為該市場概述了一個有吸引力的投資建議矩陣。
• 它還提供了有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景、主要參與者採用的競爭戰略等方面的重要見解。
• 根據公司亮點、產品組合、主要亮點、財務業績和戰略等參數介紹全球皮膚纖維化治療市場主要參與者的概況。
• 本研究涵蓋的主要公司包括 Pharmaaxis、Jubilant Cadista、Horizo□□n Pharma USA、Pfizer、Sanofi、F. Hoffmann-La Roche、Boehringer Ingelheim、Bristol-Myers Squibb Company
• 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 《全球皮膚纖維化治療市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球皮膚纖維化治療市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第二章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況:按藥物類型
  • 按給藥途徑劃分的市場概況
  • 市場概況:按應用分類
  • 市場概況:按分銷渠道
  • 市場概況:按地區
• 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

• 市場動態
  • 司機
  • 約束因素
  • 市場機會
• 影響分析
• 市場趨勢
• 近期趨勢
• 收購和合作場景
• 技術概覽
• 監管情景
• 價格分析
• 害蟲分析

第 4 章全球皮膚纖維化治療市場:冠狀病毒 (COVID-19) 大流行的影響

• 總體影響
• 政府舉措
• COVID-19 對市場的影響

第 5 章全球皮膚纖維化治療市場:按藥物類型，2017-2030

• 腎上腺皮質類固醇
• 抗纖維化藥物
• 免疫治療藥物
• 其他（免疫抑製劑）

第 6 章全球皮膚纖維化治療市場:按給藥途徑，2017-2030

• 口服劑
• 父母代理人
• 其他（地方政府）

第 7 章全球皮膚纖維化治療市場:按應用，2017-2030

• 硬皮病的局部形式
• 嗜酸性筋膜炎
• 硬皮病粘液性水腫（丘疹性粘蛋白病）
• 硬水腫

第 8 章全球皮膚纖維化治療市場:按分銷渠道，2017-2030

• 醫院藥房
• 零售藥房
• 在線藥店

第 9 章全球皮膚纖維化治療市場:地區，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲地區
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第10章競爭格局

• Pharmaxis
• Jubilant Cadista
• Horizon Pharma USA
• Pfizer
• Sanofi
• F. Hoffmann-La Roche
• Boehringer Ingelheim
• Bristol-Myers Squibb Company

第 11 章章節

• 調查方法
• 關於出版商

Skin fibrosis generally occurs in patients who suffer from eosinophilia-myalgia syndrome, scleromyxedema (papular mucinosis) and scleredema. Fibrosis frequently develops as a result of continuous chemical exposure or trauma that causes epidermal or dermal harm. It is characterized by an increase of fibrous connective tissues in the dermis or subcutis and frequently goes hand in hand with persistent inflammation. Fibrosis frequently develops as a result of epidermal or dermal damage brought on by repeated chemical exposure or trauma. An increase in fibrous connective tissues in the dermis is one of its defining features. Systemic sclerosis (SSc also known as scleroderma), which also causes fibrosis in a number of other organs, is characterized by the primary symptom of skin fibrosis. Although, this fibrosis cannot be reversed, it can be treated to some extent using currently available drugs. Dermal fibrosis, which results from a pathologic reaction to wound healing, is excessive skin scarring. Scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, and eosinophilic fasciitis are only a few of the many fibrotic skin illnesses that exist.

Market Dynamics

The rise in recent advances in treatment for the skin fibrosis is expected to drive the global skin fibrosis treatment market growth over the forecast period. For instance, in December 2017, according to the data published by the Springer Nature, the new treatment strategy has shown promising results in the treatment of skin fibrosis. The treatment involves the molecular targeting therapy with monoclonal antibody. The positive clinical outcomes had been reported in rituximab (an anti-CD20 antibody) and the tocilizumab (an anti-interleukin-6 (IL-6) receptor antibody).

Key features of the study:

• This report provides an in-depth analysis of the global skin fibrosis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global skin fibrosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pharmaxis, Jubilant Cadista, Horizon Pharma USA, Pfizer, Sanofi, F. Hoffmann-La Roche, Boehringer Ingelheim, , Bristol-Myers Squibb Company
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global skin fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin fibrosis treatment market

Detailed Segmentation:

• Global Skin Fibrosis Treatment Market, By Drug Type:
  • Corticosteroids
  • Antifibrotic Drugs
  • Immunotherapy Drugs
  • Other (Immunosuppressant)
• Global Skin Fibrosis Treatment Market, By Route of Administration:
  • Oral
  • Parenteral
  • Others ( Topical)
• Global Skin Fibrosis Treatment Market, By Application:
  • Localized forms of scleroderma
  • Eosinophilic fasciitis
  • Scleromyxedema (papular mucinosis)
  • Scleredema
• Global Skin Fibrosis Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Skin Fibrosis Treatment Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Pharmaxis
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Jubilant Cadista
  • Horizon Pharma USA
  • Pfizer
  • Sanofi
  • Hoffmann-La Roche
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Application
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pricing Analysis
• PEST Analysis

4. Global Skin Fibrosis Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Skin Fibrosis Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Antifibrotic Drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Immunotherapy Drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Other (Immunosuppressant)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Skin Fibrosis Treatment Market, By Route of Administration, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Other (Topical)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Skin Fibrosis Treatment Market, By Application, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Localized forms of scleroderma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Eosinophilic fasciitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Scleromyxedema (papular mucinosis)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Scleredema
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Skin Fibrosis Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global Skin Fibrosis Treatment Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application , 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Pharmaxis
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Jubilant Cadista
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Horizon Pharma USA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

11. Section

• Research Methodology
• About Us